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Several N4-substituted aminobenzenesulfonamides derivatives have been synthesized and structural analyses have been 
carried out using FT-IR, UV-Vis, 1H and 13C NMR, LC-MS-MS and elemental analyses. Photoluminescence and 
physicochemical properties have also been conducted. Two 4-aminobenzenesulfonamides have been treated with 2-
bromopropionyl bromide in pyridine to give their respective bromo substituted aminobenzenesulfonamides as intermediates. 
Subsequent reactions with morpholino-, thiomorpholino- and piperazine amines have yielded novel 
aminobenzenesulfonamide derivatives. As it is well known that CA IX and CA XII enzymes play an active role in attacking 
various cancerous conditions, studies presented in this study target these enzymes with in vitro cytotoxicity studies being 
performed on the compounds synthesized. The target compounds have been found to be active against some cancerous cells, 
with mimimal effects on normal cells. The physicochemical data reveal interesting synergistic effects controlling 
cytotoxicities, where the lipophilicity and polarity combinations play important roles on the eventual observed 
cytotoxicities. Further, the electronegativity and availability of the electrons of the heteroatoms of the synthesized 
compounds appear to have an effect on cancer cell cytotoxicities. 
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physicochemical properties 
Sulfonamides are known to be first drugs used 
systematically as chemotherapeutic agents against 
various diseases by way of interfering with diseased 
cell metabolism. Earlier research of sulfonamides has 
shown their use in the treatment of ill conditions, such 
as, urinary tract infections1, bronchitis2, prostatitis3, 
antiepileptic activity4 and diabetic disorders5, as well 
for many other disfunctions. Further, the literature 
provides numerous examples of sulfonamides used as 
anticancer agents6,7. Luo et al. reported new cinnamic 
acyl sulfonamides exhibiting antiproliferative 
activities against the MCF-7 human breast cancer cell 
lines8. In a previous study 4-(2-methylacetylamino) 
benzenesulfonamides were synthesized and shown to 
possess in vitro anti-cancer properties against cancer 
cells, unaffecting the normal non-cancerous cells used 
in the study
9
. Kachaeva et al. studied several 
sulfonamide E7010 derivatives for their respective 
anticancer properties against cancer cell lines using 
QSAR molecular docking experiments, and reported 
these compounds as offering promise as new 
candidates for anti-cancer therapy10. While 
sulfonamides were originally developed as carbonic 
anhydrase (CA) inhibitors for glaucoma and as 
diuretics, today sulfonamides are mainly used to 
target tumor related CA isoenzymes and CA 
overexpression in cancerous states11. Further, CA 
isoforms CA IX and CA XII have been reported to be 
associated with tumor progression and therapy12-14. 
Hence, CA enzyme inhibition is an attractive 
therapeutic approach in combating cancerous states in 
cancer therapy. McDonald et al. showed tumor cell 
survival and proliferation being favoured 
in acidic environments14, where CA IX inhibition 
studies of tumor cells resulted in decreases in 
intracellular pH and increases extracellular pH and 
hence ultimate cell death, also reported by Gatenby 
and Gillies15. 
The design of new sulfonamides is actively 
ongoing for the elusive goal of offering alternate 
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and effective drugs in selectively targeting  
cancerous cells. In this study, new substituted 
aminobenzenesulfonamide derivatives were 
synthesized and subsequently tested for in vitro 
cytotoxicity activities using the cytotoxity MTT assay 
technique. The structures presented herein bear 
sulfonamide moieties connected via propanamide 
linkages to morpholino- and thiomorpholino- 
heterocycles and were examined for anticancer 
activities against several cancer lines and were 
compared to normal non-cancerous cell lines. 
Results And Discussion 
Chemistry 
Scheme I illustrates the synthesis of two 2-bromo 
N4-substituted benzenesulfonamides 3,4 followed by 
subsequent derivatization to the target substituted 
morpholino-, thiomorpholino- and piperazine 
aminobenzenesulfonamides derivatives 5-8. 4-
Aminobenzenesulfonamide 1 and 4-(2-aminoethyl) 
benzenesulfonamide 2 were reacted with 2-
bromopropionyl bromide, separately, in pyridine 
solvent to give bromo substituted amides as the key 
intermediates 3 and 4, respectively. These were then 
treated with the morpholino-, thiomorpholino- and 1-
ethylpiperazine secondary amines in dry THF, in 
separate reactions, to obtain desired derivatives 
5-8, as white solid products in 70-80% yields.
The characterizations of the target N4-substituted
aminobenzenesulfonamide derivatives 5-8 were 
carried out using FT-IR, UV-Vis, 1H and 13C NMR, 
LC-MS-MS and elemental analyses and the respective 
data are given in the experimental section. The 
spectral bands and NMR data of synthesized 




Cytotoxic assessments of the newly synthesized 
N4-substituted aminobenzenesulfonamides derivatives 
5-8 were carried using the in vitro MTT assay
technique against six cancer cell lines, including
human prostate cancer (PC-3 and DU-145), human
colorectal adenocarcinoma (HT-29), cervix carcinoma
(HeLa), colorectal adenocarcinoma (DLD-1) and
endometrial carcinoma (ECC-1), and were compared
for their effects in normal non-cancerous human
prostate epithelium (PNT-1A) and embryonic kidney
(HEK-293). Table I provides the IC50 values of
synthesized compounds. Cells were subjected to
propagation using DMEM-F12 and RPMI-1640
media, and media supplements foetal bovine serum
(10 %), L-glutamine (2mM), penicillin (100 U/mL)
and streptomycin (100 mg/mL) in a humidified
atmosphere (5% CO2) were provided at 37 °C. The
cell cultures were harvested using 0.25% trypsin
(Sigma), upon reaching 70-80% confluence, as
recommended by ATCC.
MTT-based cytotoxicity assay 
Cytotoxic activities were determined by the 
colorimetric 3-(4, 5-dimethylthiazol-2-yl)-2, 
5-diphenyl tetrazolium bromide (MTT) assay, where
the reduction of MTT by mitochondrial
dehydrogenase of viable cells leads to the formation
of purple formazan product, spectrophotometrically
detected by UV-Vis measurements13. MTT
Scheme I — Reaction diagram for the synthesis of N4-substituted aminobenzenesulfonamides 5-8 




colorimetric assays were carried out as described in 
our previous work9. Briefly, 96 microwell plates were 
used, and were seeded (5.0 x 104 cells/well) and 
incubated at 37 °C for 24 h, prior to the addition of 
the test compounds. The cells were treated with the 
test compounds of various concentrations (1, 5, 10, 
25, 50, 100 and 200 μM) and incubated for a further 
48 h at 37 °C. Upon medium removal, cells were 
incubated with 100 μL MTT solution (5 mg/mL) at 37 
°C for 4 h. Upon the removal of the MTT solution, 
followed by dissolution with 100 μL DMSO, the 
optical absorbances were measured at 570 nm. 
Cytotoxicities were determined with reference to the 
negative controls and expressed as the mean 
percentage increase relative to unexposed controls; 
the results were mean ± standard deviation of 
triplicate readings. Control values were set as 100% 
cytotoxicity, and where necessary cytoxicity data 
were fitted to sigmoidal curves and a four-parameter 
logistic model for calculating IC50 values; IC50 was 
the concentration required to inhibit 50% cancer cell 
growth. The positive control used was 5-fluorouracil 
(5-FU). Results are given in Table I. 
The newly synthesized target compounds 5-8 were 
tested for cytotoxic activities, where the data were 
expressed as IC50 and are provided in Table I. The 
target compounds 5-8 revealed cytotoxic effects 
against various cells studied, with no remarkable 
cytotoxicity and only minimal effects on normal non-
cancerous cells. 
Compound 5 of morpholino- sulfamoylphenyl 
propanamide structure exhibited weak cytotoxicity 
against the HT-29 cell type with IC50 value 231.00 
μM. Compound 5 exhibited weak cytotoxicity against 
the HT-29 cell type with no cytotoxicity on normal 
cells. Compound 6 of morpholino (sulfamoylphenyl) 
ethylpropanamide structure, with one carbon 
extension of the main amide chain, had cytotoxic 
effect on DU-145 and HT-29, however was active 
against normal cells. This slight chain elongation can 
result an increase in lipophilic character of the 
compound. It was observed that compound 7 had 
cytotoxic effects on DLD-1 and ECC-1 cell type 
whilst no cytotoxicity on normal cells was observed. 
The commonly used chemotherapeutic agent 5-
fluorouracil (5-FU) served as the positive control for 
evaluating the chemotherapeutical effects. Cytotoxic 
effect of 7 on DLD-1 cell type can be considered 
remarkable due to lower IC50 values compared with 
compound 1 and 5-FU. Compound 8 was 
considerably active against PC-3 and DLD-1 cell 
types and moderately so for the HeLa cell type, while 
unaffecting normal cells. 
 
Lipophilicity and electronic properties 
Physicochemical properties of newly synthesized 
substituted aminobenzenesulfonamide derivatives 
were carried to assertain correlations of the biological 
activities of synthesized compounds with 
physicochemical descriptors20-22. Several molecular 
descriptors of the synthesized substituted 
aminobenzenesulfonamide derivatives are given in 
Table II. 
Lipophilicity or partition coefficient may be 
described as logP and can provide important 
information regarding the passage of compounds 
through membranes for pharmacological effects. Log 
P was positive for lipophilic and negative for 
hydrophilic samples. 
Table II shows the synthesized propionamide 
structures 5, 7 and 8 had the greatest lipophilicities. 
The precursor compound sulfanilamide 1 had greater 
Table I — Measured IC50 values of precursors 1 and 2, and N
4-substituted benzenesulfonamides 5-8 against  




Cancer Cell Normal Cell 
PC-3 DU-145 HT-29 HeLa DLD-1 ECC-1 PNT1-A HEK-293 
1 >250 >250 >250 >250 36.19 23.63 >250 >250 
2 >250 >250 >250 111.00 >250 >250 >250 >250 
5 >250 >250 231.00 >250 >250 >250 >250 >250 
6 >250 116.00 204.00 >250 >250 >250 139.00 42.00 
7 >250 >250 >250 >250 26.12 47.35 >250 >250 
8 57.67 >250 >250 180.12 73.12 >250 >250 >250 
5-FU 45.20 37.40 23.40 19.20 50.90 30.20 142.10 65.30 
aMean IC50 value of three independent readings. 
bIC50 values determined at 48 h treatment period. 




lipophilicity than the synthesized compounds 6-8. 
Interestingly, compounds 7, 8 and precursor 
compound 1 gave the greatest cytotoxic effects on 
DLD-1, ECC-1 and PC-3 cell types, where compound 
7 had the greatest cytotoxic effect (IC50 26.12 μM on 
DLD-1 and 47.35 μM on ECC-1), followed by 
precursor compound 1 (IC50 36.19 μM on DLD-1 and 
23.63 μM on ECC-1), and finally compound 8 (IC50 
73.12 μM on DLD-1 and 57.67 μM on PC-3). While 
compound 7 stems from 4-aminobenzenesulfonamide, 
amino substituted with the three-atom chain 
propionamide structure, having with a 
thiomorpholino- group at position-2 of the amino 
chain, compound 8 of similar structure, also with the 
three-atom propionamide chain, having a piperazine, 
para-substituted with an ethyl group (N4-ethyl  
group substitution). The precursor compound 1  
was 4-aminobenzenesulfonamide compound, with 
unsubstituted amino group at the para position. Chain 
elongation of the para amino group gives  
the second precursor compound 2 being 4-(2-
aminoethyl)benzenesulfonamide. In regard to the 
synthesized compounds, it seemed that 
electronegativity of the para- oxa, sulfa and aza atoms 
played a dominating role on cancer cell cytotoxicity. 
Structures 5 and 6, both bear a para- oxa atom in its 
morpholino moiety, and this oxa atom has greater 
electronegativity than the sulfa and aza atoms, 
existing in the corresponding positions of the 
thiomorpholino- and piperazine structures 7 and 8, 
respectively. However, the aza atom is a much softer 
Lewis base than an oxa atom as present in structures 5 
and 6, thus leading to better electron donating 
properties, hence better hydrogen bond acceptors in 
the interactions leading to possible cancer cell death. 
Thus, a combination of electronegativity and 
availability of the electrons of these heteroatoms 
appeared to have an effect on cancer cell cytotoxicity. 
In regard to the precursor compound 1, this structure 
had high cancer cell cytotoxicity against DLD-1 and 
ECC-1 cell types, and further amino substitutions 
with an additional three-atom propionamide chain 
bearing thiomorpholino- and piperazine moieties as 
for structures 7 and 8, may preserve or improve 
cancer cell toxicities. While the aza atom as in the 
piperazine moiety of structure 8 has greater 
electronegativiy than the sulfa atom, as in the 
thiomorpholino- moiety of structure 7, this was 
outbalanced by the aza atom of piperazine structure 8 
as it was not free, but bound to an ethyl group, thus 
reducing the effective electronegativity and hydrogen 
bond accepting ability of aza atom of structure 8. 
Therefore, as a result of this N4-ethyl group 
substitution, the observed overall cytotoxic effect of 
structure 8 on cell types DLD-1 and PC-3, though 
high compared to the other compounds 2, 5 and 6, 
was less than that observed for structure 1 and more 
so for structure 7. 
Further, the dipole effects were the greatest for 
synthesized compounds 6, and 7 and precursor 
compound 1 of dipole values (μ) greater than 6.000 D, 
being 6.101, 6.901 and 6.554 D, respectively. Here it 
can be noted that while high lipophilicity is required 
for cancer cell attack, the moderately lipophilic 
compound 6 has a high dipole value. Thus, in regard 
to compound 6, it can be noted that moderate 
lipophicity and overwhelming dipole characteristics 
may have synergetics results on cell toxicity, allowing 
for the unfavorable interactions against normal human 
cell types PNT1-A, and more so on HEK-293, and 
weak cytotoxic effects on cancer cell types DU-145 
and HT-29. This was not observed for compounds 1 
and 7, as though both have great dipoles, both are also 
highly lipophilic. In contrast, compound 5 is highly 
lipophilic but has a poor dipole value.  
Thus, compound 5 had no remarkable cancer cell 
toxicity effects, just minimal effects on cancer cell 
type HT-29. 
The molecular volumes (MV), molecular 
refractivities (MR) and molecular weights (MW) of 
Table II — Various physicochemical descriptors for precursors compounds 1 and 2, and N4-substituted benzenesulfonamides 5-8 






1 -1.98 172.20 480.62 47.76 -9.305 -0.658 8.647 -1931.71 6.554 
2 -1.20 200.26 599.97 56.68 -9.797 -0.863 8.934 -2230.52 5.018 
5 -2.09 313.37 877.04 84.20 -9.580 -0.776 8.804 -3680.54 4.957 
6 -1.31 341.43 960.45 93.12 -9.602 -0.888 8.714 -3979.54 6.101 
7 -1.65 329.43 896.00 90.37 -9.106 -0.906 8.200 -3572.90 6.901 
8 -1.60 340.44 980.87 95.92 -8.984 -1.048 7.936 -3863.58 2.993 




the synthesized compounds were greater than the 
precursor compounds 1 and 2 and were in the order 
5>6>7>8, where among these, structure 8 had the 
greatest values. 
 
Energetics and electronic dipole studies 
The frontier features HOMO and LUMO of the 
structures synthesized were examined as qualitative 
details regarding the molecular structures may be 
retrieved. Structures of the synthesized compounds 
were optimized prior to data retrieval. 
Derivative 5 revealed that 58 of 103 occupied 
molecular orbitals, with the HOMO and LUMO 
orbitals computed as -9.580 and -0.776 eV, 
respectively, with energy gap (ΔE) 8.804 eV. 
Derivative 6 had 64 of 115 occupied molecular 
orbitals, with HOMO and LUMO orbitals at -9.602 
and -0.888 eV, respectively, with ΔE 8.714 eV. 
Derivative 7 revealed 58 of 103, with HOMO and 
LUMO orbitals at -9.106 and -0.906, respectively, 
with ΔE 8.200 eV. Derivative 8 gave 64 of 116 
molecular orbitals occupied, with HOMO and LUMO 
orbitals at -8.984 and -1.048 eV, respectively, with 
ΔE 7.936 eV. Table II showed that the ΔE of HOMO-
LUMO for the synthesized derivatives 7 and 8 were 
the lowest values. These differences may have some 
role on observed cytotoxic effects, where the 
observed cytotoxic effetcs of derivatives 7 and 8 were 
somewhat similar. Derivative 5 had a high dipole 
moment, possibly a favoured condition for cancer cell 
electrostatic interactions and eventual breakdown, 
however, this was surpassed by its low lipophilic 
nature, as shown in Table II, and hence the observed 
interactions against normal human cell types PNT1-A 
and HEK-293, and only weak cytotoxic effects on 
cancer cell types DU-145 and HT-29. 
 
Fourier Transform Infrared spectroscopy (FT-IR) 
measurements 
FT-IR spectra of the newly synthesized 
benzenesulfonamide derivatives 5-8 were obtained 
using U-ATR at range 4000-400 cm-1 and were 
compared those of the starting compounds to obtain 
interesting information for spectroscopic 
characterization of the novel compounds. Synthesized 
compounds 5-8 showed characteristic vibrations at 
ranges of 3340-3250 cm-1 for -NH2 sulfonamide, 
3220-3180 cm-1 for N-H amide, 1695-1630 cm-1 for 
C=O amide, 1340-1160 cm-1 for S=O sulfonamide  
as given in the experimental section. These  
confirmed formation of novel N4-substituted 
aminobenzenesulfonamides 5-8 (Figure 1). 
 
UV-Vis data analyses 
Spectrophotometric grade DMF was used for 
collecting the electronic spectra of precursors 1 and 2, 
2-bromo N4-substituted benzenesulfonamides 3 and 4 
and N4-substituted benzenesulfonamides 5-8, and are 
presented in Figure 2. 
Precursor 1 gave a strong absorption at 276 nm and 
a weak band at 306 nm; this was consistent with the 
literature values23-25. The 276 nm absorption was 
designated as the benzenoid ring π-π* transition. The 
306 nm absorption shows n-π* transitions arising 
from non-bonding electrons of the N or S atoms of 
compound 1. These two peaks observed for precursor 
1 illustrates the presence of two transition types, the 
first being strong and the most probable occurrence, 
 
 
Figure 1 — FT-IR spectra of precursors 1 and 2, 2-bromo N4-substituted benzenesulfonamides 3 and 4 and N4-substituted 
benzenesulfonamides 5-8 




and the second being much weak and occurring with 
lower chance. Figure 2 showed all the synthesized 
compounds 3-8 as having different absorption spectra 
due to their differing observed λmax, particularly for 
intermediate compound 3. Further, intermediate 
compound 3 had an intense absorption at 284 nm and 
a shoulder peak at 298 nm. Compound 3 had a main 
absorption being much broader than that of compound 1, 
shifting slightly to a higher wavelength (from 276 nm 
to 284 nm). 
Precursor 2 leads to its intermediate compound 4 
and upon reaction, as detailed out in the experimental 
section, provides derivative 6. The absorption 274 nm 
can be attributed to the π-π* transitions for 
compounds 2, 4 and 6. The main absorption peaks for 
these compounds were sharper and more attenuated 
than that of precursor 1, shifting to lower wavelength 
(from 276 nm to 274 nm). The weak band noted at 
306 nm for precursor 1 was relatively poor in 
precursor 2, and its respective intermediate 4 and its 
related derivative 6. This indicated that the n-π* 
transitions in compounds 2, 4 and 6 were less distinct, 
and the the π-π* transitions for compounds 2, 4 and 6 
were the dominating transitions. The π-π* transition 
peak intensities for compounds 2, 4 and 6 were 
greater than precursor 1. Structures bearing rich 
electronic structures may notably increase maxima 
absorption intensities. Further, chain elongation, such 
as an ethyl chain, led to higher absorption maxima 
intensities, and maxima absorption shifts as for 
compounds 2, 4 and 6 compared to the absorption 
maximum wavelength of precursor 1. The 280 nm 
absorption was designated as the π-π* transitions for 
derivatives 5, 7 and   8.   The   main   absorptions   for  
Table III — UV-Vis data for precursors 1 and 2, 2-bromo N4-
substituted benzenesulfonamides 3 and 4 and N4-substituted 
benzenesulfonamides 5-8 
Compd  (L mol-1 cm-1) max Abs (nm) In Abs 
1 8.54x10
4 276 1.196 
2 11.28x10
4 274 1.579 
3 9.11x10
4 284 1.276 
4 10.02x10
4 274 1.403 
5 12.17x10
4 278 1.704 
6 12.70x10
4 274 1.778 
7 13.61x10
4 280 1.906 
8 14.75x10
4 280 2.065 
max Abs: maximum absorption wavelength, In Abs: maximum 
absorption intensity, : molar absorptivity coefficient, sample 
concentrations: 1.4x10-5 mol/L 
 
derivatives 5, 7 and 8 were narrower than that of 
precursor 1, shifting to higher wavelengths (from  
276 nm to 280 nm). The weak band observed at  
306 nm for precursor 1 was indistinguishable  
for derivatives 5, 7 and 8, hence the π-π* transitions 
for derivatives 5, 7 and 8 were the dominating 
transitions. Derivatives 5, 7 and 8, bearing larger 
cyclic structural units, led to high π-π* transition peak 
intensities, compared to that of precursor 1. This may 
be due to these derivatives being structurally more 
cyclic and capable of donating π electrons, and can 
result in increased absorption maxima intensities. 
Among the derivatives synthesized, derivative 8 was 
observed as having the greatest absorption maximum 
intensity. 
UV-Vis data for precursors 1 and 2 and 2-bromo 
N4-substituted benzenesulfonamides 3 and 4 and N4-
substituted benzenesulfonamides 5-8 are given in 
Table III. The values of molar absorptivity 
coefficients for compounds 2-8 were greater than that 
of precursor 1. Notable increases in the molar 
absorption capacities were observed for these 
compounds compared to precursor 1. A plausible 
explanation for this may be that these structures are 
much more electron rich than precursor 1. Among the 
derivatives 5-8, derivative 8 displayed the greatest 
molar absorptivity coefficient value, where the 
differences in the values of molar absorptivity 
coefficients may be due to the structural differences, 
and respective atomic contributions to electronic 





C NMR spectroscopic analyses 
NMR spectra data of the newly synthesized 
benzenesulfonamide derivatives 5-8 are given in the 
experimental section. The NMR spectra of derivatives 
 
 
Figure 2 — UV-Vis spectra of precursors 1 and 2 and 2-bromo 
N4-substituted benzenesulfonamides 3 and 4 and N4-substituted 
benzenesulfonamides 5-8 
 




5 and 7 are provided as representative examples, and 
are given in Figure 3, Figure 4, Figure 5 and Figure 6. 
The 1H NMR spectra of derivatives 5-8 showed 
aliphatic protons in range δ 0.96-3.73 ppm, and 
aromatic protons in range δ 7.35-7.84 ppm, and are 
consistent with the literature9,26. Further, derivatives 
5-8 exhibited singlets at 7.81-10.10 ppm, these being 
attributed to the amide proton (-CONH) and at 7.23-
7.28 ppm, attributed to the sulfonamide protons (-
SO2NH2). Doublet peaks were seen for the CH3- and 
aromatic methylene proton (Ar-H) groups, both of 
which neighboured single protons. Multiplet peaks 
were noted, and assigned to the aromatic protons (Ar-
H) of benzenesulfonamide ring for all the derivatives 
and methylene (-CH2-) protons of morpholine, 
thiomorpholine and 1-ethly piperazine rings for 
derivatives 5-8. 
The 13C NMR spectra of derivatives 5-8 gave 
aliphatic methyl carbons at δ 11.37-13.47 ppm, 
particularly derivative 8 gave an extra methyl carbon 
at δ 12.49 due to 1-ethyl piperazine moiety and 
aromatic carbons at δ 119.40-144.07 ppm being 
 
 




Figure 4 — 13C NMR spectrum of derivative 5 




consistent with the literature9,26. Methylene ring 
carbons were observed in the region 27.92-64.17 
ppm, where shift values depended on the ring size and 
type. The amide carbon (-CONH) was observed in the 
region 172.16-172.60 ppm. Several aromatic carbons 
had the exact same NMR signal, due to the symmetry 
of the molecular structures9,26. 
 
Mass spectral (LC-MS-MS) evaluations 
The molecular mass data of the newly synthesized 
benzenesulfonamide derivatives 5-8 were collected 
and spectral analysis revealed the formation of the 
target compounds. The mass spectra of derivatives 5 
and 7 are given as representative examples, and are 
provided in Figure 7 and Figure 8, respectively. Data 
collected support the formation of target derivatives 
which were detected as single sharp peaks, indicative 
of the [M+H]+ ions. 
 
Fluorescence spectroscopy measurements 
Fluorescence spectra for precursors 1 and 2 and 
compounds 3-8, with excitation at 264 nm, were 
evaluated. Upon irradiation by UV light, precursors  
1 and 2 and compounds 3-8 provided strong 
fluorescence emissions. The fluorescence spectra  
for precursors 1 and 2, 2-bromo N4-substituted 
 
 




Figure 6 — 13C NMR spectrum of derivative 7 
 




benzenesulfonamides 3 and 4 and N4-substituted 
benzenesulfonamides 5-8 are given in Figure 9. 
The maximum luminescent intensity for precursor 
1 was 348 nm, having a full width at half maximum 
(FWHM) of 48 nm. Further, precursor 1 provided a 
quantum yield of 27 %, and excited-state lifetime of 
2.57 ns. The maximum luminescent intensity for 
derivative 8 was 391 nm, with its respective FWHM 
being 106 nm, and a quantum yield of 37 % and 3.48 
ns excited-state lifetime. Increasing electron donating 
groups at ring para-positions caused increases in the 
main peak intensities, as observed for compounds 2 
and 4-8, shifting to higher emission wavelengths. 
Extended molecular structures bearing high -electron 
delocalizations or the existence of electron rich cyclic 
molecules result in high quantum yields and increases 
in fluorescence emission intensities. Electron rich 
structures improve electron delocalizations and/or 
energy transfers from derivative excited states and 
leds to decreases in the non-radiated transitions of the 
derivatives and eventual increases of fluorescence 
emissions. Further, attachments of electron 
withdrawing   groups   at  ring   para- positions  as  for  
 
 
Figure 9 — Fluorescence spectra for precursors 1 and 2, 2-bromo 
N4-substituted benzenesulfonamides 3 and 4 and N4-substituted 
benzenesulfonamides 5-8 in DMF, with excitation at 264 nm 
 
compound 3 results in main peak intensity decreases, 
shifting to lower emission wavelengths as reported 
earlier9. These electron withdrawing groups pull 
electrons and reduce the possibility of emissions from 
cyclic derivative excited states. The fluorescence 
spectral data for precursors 1 and 2, 2-bromo  
 
 




Figure 8 — Mass spectrum of derivative 7 
 




N4-substituted benzenesulfonamides 3 and 4 and N4-




Materials and chemicals 
Chemicals, solvents and reagents were purchased 
from commercial suppliers and were used without 
further purification unless indicated in the procedures. 
 
Instrumentation and measurements 
A LECO CHNS-932 Elemental Analyser was  
used for elemental analysis detections. FT-IR spectra 
were collected using a Perkin Elmer Spectrum  
Two FT-IR Spectrometer. Electronic absorption 
spectra were measured using a Perkin Elmer Lambda 
25 UV-Vis Spectrophotometer. A Perkin Elmer  
LS55 Spectrofluorophotometer was used for the 
fluorescence measurements using quartz sample cells 
of 1 cm optical path and sample concentrations in 
DMF being 1.0 × 10-5 molL-1, and the applied 
excitation wavelength 264 nm. Photoluminescence 
quantum yield measurements were taken using the 
standard 9,10-diphenylantracene16-18. An Agilent-
VNMRS-400 Spectrometer was used for NMR data 
(1H NMR 400 MHz, 13C NMR 100 MHz) collections, 
utilizing DMSO-d6 as the solvent and TMS as the 
internal standard. An Electrothermal 9100 melting 
point apparatus was used for the melting point 
readings. Mass spectral data were collected using a 
Shimadzu LCMS 8040 Model Spectrometer. Purity 
assessments and reaction progress were followed 
using chromatography plates (Merck Silica Gel 60 
F254). 
 
In vitro Cytotoxic Activity 
Cell culture preparation 
Cells studied were provided by the American Type 
Culture Collection (ATCC, Manassas, Virginia). Cell 
types investigated were cancerous human  
prostate (PC-3 and DU-145), human colorectal 
adenocarcinoma (HT-29), cervix carcinoma (HeLa), 
colorectal adenocarcinoma (DLD-1), endometrial 
carcinoma (ECC-1) cell types, and normal prostate 
epithelium PNT-1A and embryonic kidney (HEK-
293). Cells were subjected to propagation processes, 
with supplements of foetal bovine serum, L-
glutamine, penicillin and streptomycin in a 37 °C 
humidified atmosphere as described previously9. 
Upon reaching 70–80% confluence, the cells were 
harvested as recommended by ATCC. 
 
Cytotoxicity and IC50 determination 
The reduction of (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) (MTT) detected 
spectrophotometrically as blue formazan production, 
allowed for cytotoxicity evaluation13. Using a 
literature procedure, 96 well plates was used for the 
MTT colorimetric assays, seeded at concentration 5.0 
×104 cells/well with 37 °C incubations for 24 h 9. The 
test concentrations used were 1, 5, 10, 25, 50, 100 and 
Table IV — Fluorescence data for precursors 1 and 2, 2-bromo N4-substituted benzenesulfonamides 3 and 4 and N4-substituted 
benzenesulfonamides 5-8 









































































































max Ex: maximum excitation wavelength; In Ex: maximum excitation intensity; 
max Em: maximum emission wavelength; In Em: maximum emission intensity; 
f : quantum yield; f : excited-state lifetime. 
 




200 μM, with data collections carried out triplicate 
readings and negative controls as the reference. 
 
Physicochemical properties studies 
Some parameters were calculated in order to 
establish the relationship between the evaluation of 
physicochemical properties and biological processes. 
Physiochemical descriptors were examined using 
HyperChem19. Molecular Mechanics Force Field 
(MM+) method was used for pre-optimizations and 
refinements by the semiempirical PM3 procedure. 
 
General procedure for synnthesis of 2-bromo-N-(4-
sulfamoylphenyl)propanamide 3 and 2-bromo-N-
(4-sulfamoylphenethyl)propanamide, 4 
A 10.00 mmol solution of 2-bromopropionyl 
bromide in 40 mL THF was slowly added to a 10.00 
mmol solution of either 4-aminobenzenesulfonamide 
1 or 4-(2-aminoethyl) benzenesulfonamide 2 and 
15.00 mmol pyridine in 30 mL THF at 0oC. Upon 
warming to room temperature, the reaction was stirred 
for a further 22 h to give white solids 3 and 4, 
respectively, as described in the literature method9. 
 
2-Bromo-N-(4-sulfamoylphenyl)propanamide, 3 
Title compound 3 was a white solid (70%): m.p. 
217-219 oC. FT-IR (U-ATR, cm-1): 3333, 3207 (NH2), 
3129 (Amide-N-H), 3071 (Ar-C-H), 2927, 2980 
(Aliph.-C-H), 1683 (Amide-C=O), 1331 
(Asymmetric), 1160 (Symmetric) (S=O), 541 (C-Br); 
1H-NMR (DMSO-d6, TMS, 400 MHz, δ ppm): 10.66 
(1H, s, H-N-C=O), 7.71-7.77 (4H, m, J= 8 Hz, -Ar-
H), 7.27 (2H, s, SO2NH2), 4.66-4.71 (1H, q, J= 8 Hz, 
Br-CH-), 1.72-1.74 (3H, d, J= 8 Hz, -CH3); 
13C-NMR 
(DMSO-d6, TMS, 100 MHz, δ ppm): 168.44 (C=O), 
141.89 (Ar-C-NH-), 139.37 (Ar-C-SO2NH2), 127.22 
(Arom.), 119.39 (Arom.), 44.56 (CH-Br), 21.64 
(CH3); LC-MS/MS Mass (m/z): 307.8 [M+H]; 
Calculated for C9H11BrN2O3S (307.16 g/mol) (%):  
C, 35.19; H, 3.61; N, 9.12; S, 10.44. Found (%):  
C, 35.10; H, 3.67; N, 9.19; S, 10.35. 
 
2-Bromo-N-(4-sulfamoylphenethyl)propanamide, 4 
Title compound 4 was a white solid (70%): m.p. 
159-161 oC. FT-IR (U-ATR, cm-1): 3342, 3296 (NH2), 
3211 (Amide-N-H), 3095 (Ar-C-H), 3004,  
2872 (Aliph.-C-H), 1655 (Amide-C=O), 1337 
(Asymmetric), 1161 (Symmetric) (S=O), 554 (C-Br); 
1H-NMR (DMSO-d6, TMS, 400 MHz, δ ppm):  
8.33 (1H, s, H-N-C=O), 7.36-7.38 (2H, m, J= 8 Hz, -
Ar-H), 7.70-7.72 (2H, m, J= 8 Hz, -Ar-H), 7.28  
(2H, s, SO2NH2), 4.40-4.45 (1H, q, J= 8 Hz, Br-CH-), 
3.27-3.32 (2H, m, N-CH2); 2.76-2.79 (2H, d, J= 8 Hz, 
Ar-CH2); 1.59-1.61 (3H, d, J= 8 Hz, -CH3); 
13C-NMR 
(DMSO-d6, TMS, 100 MHz, δ ppm): 169.02 (C=O), 
143.56 (Ar-C-(CH2)2-NH-), 142.26 (Ar-C-SO2NH2), 
129.35 (Arom.), 125.79 (Arom.), 44.18 (CH-Br), 
40.18 (CH2-NH-), 34.51 (Ar-CH2), 21.91 (CH3);  
LC-MS/MS Mass (m/z): 336.2 [M+H]; Calculated for 
C11H15BrN2O3S (335.22 g/mol) (%): C, 39.41;  
H, 4.51; N, 8.36; S, 9.57. Found (%): C, 39.33; H, 
4.58; N, 8.47; S, 9.51. 
 




The syntheses of the title compounds were carried 
in a similar way to that described in the literature9. 
Briefly, mixtures of 1.5 equivalent samples of 
morpholine for the synthesis of 5, thiomorpholine for 
7 or 1-ethyl piperazine for 8 and a 1.0 equivalent 
sample of pyridine in 20.0 mL THF was slowly added 
to 10.00 mmol 2-bromo-N-(4-sulfamoylphenyl) 
propanamide 3 in 30 mL THF at 0 oC as separate 
reactions, over a period of 30 minutes. In the same 
manner, a mixture of a 1.5 equivalent sample of 
morpholine in 20.0 mL THF for the synthesis of  
6 was slowly added to 10.00 mmol 2-bromo-N-(4-
sulfamoylphenethyl)propanamide 4 in 30 mL THF at 
0 oC, over a period of 30 minutes. Upon warming to 
room temperature, reactions were stirred at 40 oC for 
48 h. All reactions were monitored by TLC 
(DCM/methanol). Recrystallizations were carried out 
for solid products using ethanol, and subsequently 




Title compound 5 was a white solid (75%): m.p. 
181-183 oC. FT-IR (U-ATR, cm-1): 3339, 3308 (NH2), 
3219 (Amide-N-H), 3089 (Ar-C-H), 2960-2830 
(Aliph.-C-H), 1652 (Amide-C=O), 1336 
(Asymmetric), 1159 (Symmetric) (S=O); 1H-NMR 
(DMSO-d6, TMS, 400 MHz, δ ppm): 10.10 (1H, s, -
CONH), 7.78-7.80 (2H, d, J=8 -Ar-H), 7.72-7.74 
(2H, d, J=8, -Ar-H), 7.23 (2H, s, SO2NH2), 3.58-3.61 
(4H, t, J=8, -CH2-O-CH2), 3.21-3.27 (1H, q, -N-CH-
CH3), 2.51-2.60 (4H, m, -CH2-N-CH2), 1.17-1.18 (3H, 
d, J=4 Hz -CH3); 
13C-NMR (DMSO-d6, TMS, 100 
MHz, δ ppm): 172.16 (C=O), 142.03 (Ar-C-NH-), 
138.92 (Ar-C-SO2NH2), 127.01 (Arom.), 119.46 
(Arom.), 66.78 (CH3-CH-N), 64.17 (CH2-O-CH2), 
50.08 (CH2-N-CH2), 12.97 (CH3); LC-MS/MS Mass 




(m/z): 314.10 [M+H]; Calculated for C13H19N3O4S 
(313.37 g/mol) (%): C, 49.83; H, 6.11; N, 13.41; S, 





Title compound 6 was a white solid (70%): m.p. 
144-146 ˚C. FT-IR (U-ATR, cm-1): 3338, 3320 (NH2), 
3210 (Amide-N-H), 3102 (Ar-C-H), 2982-2835 
(Aliph.-C-H), 1630 (Amide-C=O), 1338 
(Asymmetric), 1162 (Symmetric) (S=O); 1H-NMR 
(DMSO-d6, TMS, 400 MHz, δ ppm): 7.81 (1H, s, -
CONH), 7.71-7.69 (2H, d, J=8, -Ar-H), 7.37-7.35 
(2H, d, J=8 -Ar-H), 7.28 (2H, s, SO2NH2), 3.73-3.71 
(2H, m, N-CH2); 3.38-3.33 (1H, q, -N-CH-CH3), 
3.06-3.04 (2H, d, J= 8 Hz, Ar-CH2); 2.83-2.78 (4H, t, 
J=8, -CH2-O-CH2), 2.31-2.22 (4H, m, -CH2-N-CH2), 
1.02-1.00 (3H, d, J=4 Hz -CH3); 
13C-NMR (DMSO-
d6, TMS, 100 MHz, δ ppm): 172.60(C=O), 144.07 
(Ar-C-NH-), 142.47 (Ar-C-SO2NH2), 129.59 (Arom.), 
126.02 (Arom.), 66.68 (CH3-CH-N), 63.92 (CH2-O-
CH2), 50.27 (CH2-N-CH2), 39.63 (CH2-NH-), 35.11 
(Ar-CH2), 13.47 (CH3); LC-MS/MS Mass (m/z): 
342.10 [M+H]; Calculated. for C15H23N3O4S  
(341.43 g/mol) (%): C, 52.77; H, 6.79; N, 12.31;  





Title compound 7 was a white solid (80%): m.p. 
186-187°C. FT-IR (U-ATR, cm-1): 3330, 3292 (NH2), 
3190 (Amide-N-H), 3105 (Ar-C-H), 2987-2819 
(Aliph.-C-H), 1661 (Amide-C=O), 1328 
(Asymmetric), 1148 (Symmetric) (S=O); 1H-NMR 
(DMSO-d6, TMS, 400 MHz, δ ppm): 10.06 (1H, s, -
CONH), 7.82-7.84 (2H, d, J=8 -Ar-H), 7.75-7.77 
(2H, d, J=8, -Ar-H), 7.26 (2H, s, SO2NH2), 2.79-2.77 
(4H, t, J=8, -CH2-N-CH2), 3.38-3.43 (1H, q, -N-CH-
CH3), 2.67-2.69 (4H, m, -CH2-S-CH2), 1.15-1.17 (3H, 
d, J=4 Hz -CH3); 
13C-NMR (DMSO-d6, TMS, 100 
MHz, δ ppm): 172.16 (C=O), 142.04 (Ar-C-NH-), 
138.91 (Ar-C-SO2NH2), 127.04 (Arom.), 119.46 
(Arom.), 64.55 (CH3-CH-N), 51.78 (CH2-N-CH2), 
27.92 (CH2-S-CH2), 11.37 (CH3); LC-MS/MS Mass 
(m/z): 330.10 [M+H]; Calculated. for C13H19N3O3S2 
(329.44 g/mol) (%): C, 47.40; H, 5.81; N, 12.76; S, 




Title compound 8 was a white solid (70%): m.p. 
221-222 ˚C. FT-IR (U-ATR, cm-1): 3297, 3252 (NH2), 
3180 (Amide-N-H), 3043 (Ar-C-H), 2984-2790 
(Aliph.-CH2), 1694 (Amide-C=O), 1328 
(Asymmetric), 1159 (Symmetric) (S=O); 1H-NMR 
(DMSO-d6, TMS, 400 MHz, δ ppm): 10.06 (1H, s, -
CONH), 7.75-7.82 (4H, m, J=8, -Ar-H), 7.26 (2H, s, 
SO2NH2), 2.40 -2.54 (8H, m, N-CH2-CH2-N), 3.24-
3.29 (1H, q, CH3-CH-N); 2.28-2.33 (2H, q, CH3-CH2-
N); 1.17-1.18 (3H, d, J=4 Hz CH3-CH); 0.96-0.99 
(3H, t, J=4 Hz CH3-CH2-N); 
13C-NMR (DMSO-d6, 
TMS, 100 MHz, δ ppm): 172.37 (C=O), 142.02  
(Ar-C-NH-), 138.87 (Ar-C-SO2NH2), 127.06 (Arom.), 
119.40 (Arom.), 64.04 (CH3-CH-N), 53.02 (CH2-
N(CH2CH3)-CH2), 52.04 (CH2-N(CHCH3)- CH2), 
49.50 (CH3-CH2-N); 12.92 (-CH-CH3); 12.49 (CH3-
CH2-N); LC-MS/MS Mass (m/z): 341.10 [M+H]; 
Calculated. for C15H24N4O3S (340,44 g/mol) (%): C, 
52.92; H, 7.11; N, 16.46; S, 9.42. Found (%): C, 






derivatives were synthesized and subsequently studied 
for spectroscopic and potential biological activities. 
Fluorescence studies showed the derivatives as having 
greater intensities and efficiencies than that of 
precursor 1. Physicochemical data were collected  
and discussed, and correlated with the observed  
in vitro cytotoxicity activities. The lipophilicities  
and polarities of the synthesized compounds  
were evaluated, and synergistic effects optimally 
controlling cytotoxicity activities were noted, such 
that, high lipophilicity and low polarity combinations 
were not a preferred combination, as for derivative 5. 
High lipophilicities and high polarities, worked in a 
synergistic manner to offer both hydrogen bonding 
and electrostatic capabilites for cancer cell targets, as 
for observed for derivatives 7 and 8. Lower 
lipophilicities and high polarities, though gave 
unremarkable activities, were an undesired 
combination, targeting normal cells as observed for 
derivative 6. The results of the synthesized derivatives 
may be used to further develop carbonic anhydrase 
inhibitory drugs. The photophysical data may  
offer potential use in the analytical techniques  
of medicine. 
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